Top Net Payout Yield Stocks To Own Right Now

Top Net Payout Yield Stocks To Own Right Now: EnteroMedics Inc.(ETRM)

EnteroMedics Inc., a clinical development stage medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity and associated co-morbidities, and other gastrointestinal disorders. The company?s proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. Its product under development is the Maestro System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. The company intends to market its products to potential referral source clinicians, including general practitioners, internists, endocrinologists, and nurses. It has collaboration agreement with Mayo Clinic and Australian Institute of Weight Control. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003 . EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.

Advisors' Opinion:

• [By John Udovich]

  On Tuesday, small cap EnteroMedics Inc (NASDAQ: ETRM) soared 63.5% after reporting new clinical trial data for its Maestro system that is designed to control obesity, meaning it might be time to take a closer look at the stock along with the performance of other small cap obesity drug or treatment players like Arena Pharmaceuticals, Inc (NASDAQ: ARNA), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS).

• [By John Udovich]

  Small cap biotech Arena Pharmaceuticals, Inc (NASDAQ: ARNA) soared yesterday and last Friday on earnings as well as news that the company will expand its marketing and supply agreement with Japan based Eisai for its BELVIQ (lorcaserin HCl) obesity drug, meaning it might be time to take a closer look at other biotech stocks like Orexigen ! Therapeutics, Inc (NASDAQ: OREX), EnteroMedics Inc (NASDAQ: ETRM) and VIVUS, Inc (NASDAQ: VVUS) that are in the business of treating obesity. Specifically, Arena Pharmaceuticals announced an expanded agreement providing Eisai with exclusive commercialization rights for all countries worldwide (except for South Korea, Taiwan, Australia, Israel and New Zealand) for BELVIQ where Arena will receive an upfront payment of $60 million and is eligible to receive up to a total of $176.5 million in regulatory and development milestone payments - an increase of $123 million from the amount remaining available under the previous agreement. BELVIQ was a pproved in June 2012, but didn't reach the market until June 2013 due to logistical concerns like classification by the Drug Enforcement Administration. Its alsoapproved for use in adults who are obese or who are overweight and who have at least one serious medical condition (e.g. diabetes or high cholesterol).

• [By James E. Brumley]

  Look out VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). There's a new weight-loss player ready to take aim at your target market, and its name is EnteroMedics Inc. (NASDAQ:ETRM). If the recent action from ETRM is any indication, the market thinks it could be a real threat to your weight-loss ventures.

source from Top Penny Stocks For 2015:http://www.topstocksforum.com/top-net-payout-yield-stocks-to-own-right-now.html